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Gooch et al present a useful summary of the burden of neuro-
logical diseases in the USA.1 Their presentation omits some
important recent findings and fails to draw a critical implication
about mitigating the burden of neurologic diseases. Gooch et al
correctly show that dementias are the costliest neurological disor-
ders, but they probably overstate the burden of dementias. Preva-
lence estimates from other sources, including those used by the
World Health Organization, suggest significantly lower preva-
lence of dementias in the USA.2 Credible recent data indicate
that the age-related incidence and prevalence of dementias is fall-
ing in the USA and other industrialized nations.3,4 In the British
Cognitive Function and Aging Studies I & II, there was a 20–
25% decline in age-specific dementia prevalence over the past
generation.4 What accounts for these large effects? Mixed demen-
tia, often with a significant vascular component, is recognized as
a major cause of dementia.5 The declining age-specific prevalence
of dementia is likely a partial consequence of the dramatic fall in
cerebrovascular disease described nicely by Gooch et al. Another
contributing factor may be a better educated population. Educa-
tion has a significant protective effect on dementia incidence,
possibly by improving cognitive reserve.6 The key implication is
that there are existing and highly cost-effective interventions that
diminish the burden of a major neurological disorder. It is
unlikely that we have exhausted the benefits of improving control
of vascular risk factors and education. Enhancing primary care
and public education is likely to yield considerable dividends in
terms of mitigating the burden of dementing disorders.
The implication that we have effective methods to reduce
disease burden through existing prevention strategies applies to
some of the other disorders described by Gooch et al. The USA
does relatively poorly, for example, in preventing serious motor
vehicle accidents, with obvious consequences for the incidence
of traumatic brain and spinal cord injury.7
Gooch et al appropriately favor increased advocacy to boost
research on and improve clinical care of neurological diseases.
Advocacy should extend to promoting public health, primary care,
and social interventions that prevent neurological disease.
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Reply to “Mitigating the Burden of Neurological
Disease”
Clifton L. Gooch, MD
We thank Dr Albin for raising these important issues, and pro-
viding us the opportunity for further exploration of some of
the critical topics raised by our article.1 It is true that several
recent studies have documented a lower than projected inci-
dence of dementia, and some have suggested an age-adjusted
decline in dementia risk.2–4 One potential explanation for these
unexpected findings, as raised by Dr Albin, is the success of
efforts directed at reducing the risk of cerebrovascular disease
(better control of hypertension and hypercholesterolemia,
decreased tobacco use, etc) resulting in a reduced incidence of
vascular brain injury and dementia. However, at the same time,
the prevalence of both obesity and diabetes in the United States
is growing unchecked, reaching epidemic levels in both younger
and older patients,5 and these developments may well reverse
any potential temporary gains wrought by better control of oth-
er cerebrovascular risk factors in the future. Consequently, the
ability to create a model of the future prevalence of dementia
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